Actively Recruiting

Phase Not Applicable
All Genders
NCT06082401

Evaluating the Addition of Hemodiafiltration to EVLP - Impact on the Regeneration of Marginal Donor Lungs

Led by Medical University of Vienna · Updated on 2025-05-14

30

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

Sponsors

M

Medical University of Vienna

Lead Sponsor

X

XVIVO Perfusion

Collaborating Sponsor

AI-Summary

What this Trial Is About

The primary objective of the study is the evaluation of the effect of hemodiafiltration during ex vivo lung perfusion in marginal donor lungs, and its feasibility. The hypothesis of this study is that this therapy could stabilize perfusate electrolyte composition, remove toxins and waste products, normalize pH levels and prevent edema formation, thereby reconditioning marginal donor lungs for transplantation. The proposed pilot study addresses the unmet clinical needs in several aspects: a) for the first time a homeostatic device will be introduced in EVLP to reach stable perfusate composition; b) the proposed modification of the standard EVLP could lead to longer perfusion times, making elective transplantation possible and setting the base for possible ex vivo lung treatments; c) the ultimate effect of the proposed study is to increase organ availability through reconditioning of marginal donor lungs.

CONDITIONS

Official Title

Evaluating the Addition of Hemodiafiltration to EVLP - Impact on the Regeneration of Marginal Donor Lungs

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Marginal donor lungs according to ISHLT criteria, including at least one of the following: PaO2/FiO2 ratio less than 400 (with FiO2=1.0 and PEEP 5-8 cmH2O), donor age 55 years or older, smoking history of 20 pack-years or more, infiltrates on chest radiograph, significant secretions in bronchoscopy, or organisms on sputum gram stain
  • Donor age greater than 18 years
Not Eligible

You will not qualify if you...

  • Bilateral consolidations in donor lungs
  • Lungs from donors with chest trauma
  • Lungs from drowned donors
  • Patients included in other interventional studies
  • Patients on intensive care unit prior to transplantation with mechanical ventilation or ECMO support
  • Patients undergoing lung retransplantation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical University of Vienna

Vienna, Austria, 1090

Actively Recruiting

Loading map...

Research Team

P

Panja M Boehm, MD

CONTACT

A

Alberto Benazzo, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluating the Addition of Hemodiafiltration to EVLP - Impact on the Regeneration of Marginal Donor Lungs | DecenTrialz